首页 > 最新文献

Swiss medical weekly最新文献

英文 中文
Supplementum 275: Abstracts of the 55th Annual meeting of the Swiss Society of Nephrology. Supplementum 275:瑞士肾脏病学会第 55 届年会摘要。
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-30 DOI: 10.57187/s.3671
Swiss Society Of Nephrology
{"title":"Supplementum 275: Abstracts of the 55th Annual meeting of the Swiss Society of Nephrology.","authors":"Swiss Society Of Nephrology","doi":"10.57187/s.3671","DOIUrl":"https://doi.org/10.57187/s.3671","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3671"},"PeriodicalIF":2.9,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Haemoglobin thresholds for transfusion: how are we doing in the era of Choosing Wisely? A retrospective cohort study 输血的血红蛋白阈值:我们在 "明智选择 "时代做得如何?回顾性队列研究
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-29 DOI: 10.57187/smw.2023.40132
Phyranavy Jeganathan-Udayakumar, Nicole Tochtermann, Thomas Beck, M. Wertli, Christine Baumgartner
INTRODUCTION: Clinical practice guidelines and the Choosing Wisely initiative launched in 2012 recommend a haemoglobin (Hb) threshold of 70–80 g/lfor red blood cell (RBC) transfusions in stable hospitalised patients. Data on transfusion practices and their trends in medical inpatients are limited. To address this gap, we investigated transfusion practices and their trends in general internal medicine and other clinics. METHODS: This retrospective cohort study analysed data from all hospitalisations with RBC transfusions at a Swiss university hospital between 2012 and 2019. We included all first transfusion episodes if pretransfusion Hb was available. The primary endpoint was mean pretransfusion Hb; secondary endpoints included potentially inadequate transfusions (i.e., transfusions at Hb ≥80 g/l) and receipt of a single RBC unit. Trends in mean pretransfusion Hb over time were estimated using generalised estimating equations, and risk factors for potentially inadequate transfusions were identified using multivariable adjusted generalised estimating equations models. RESULTS: Of 14,598 hospitalisations with RBC transfusions, 1980 (13.6%) were discharged from general internal medicine. From 2012 to 2019, mean pretransfusion Hb decreased from 74.0 g/l to 68.8 g/l in general internal medicine (mean annual decrease –0.76 g/l, 95% confidence interval [CI] –0.51 to –1.02) and from 78.2 g/l to 72.7 g/l in other clinics (mean annual decrease –0.69, 95% CI –0.62 to –0.77; p for interaction 0.53). The overall proportion of potentially inadequate transfusions was 17.8% in general internal medicine and 24.1% in other clinics (p <0.001) and decreased over the study period from 26.9% to 5.5% in general internal medicine and from 37.0% to 15.2% in other clinics. In contrast, the proportion of cases receiving a single RBC unit increased (39.5% to 81.4% in general internal medicine, 42.7% to 66.1% in other clinics). Older age (adjusted odds ratio [aOR] 1.45, 95% CI 1.32–1.58 for ≥65 vs <65 years), having surgery (aOR 1.24, 95% CI 1.14–1.36), acute haemorrhage (aOR 1.16, 95% CI 1.02–1.33), chronic heart failure (aOR 1.17, 95% CI 1.04–1.32), ischaemic heart diseases (aOR 1.27, 95% CI 1.15–1.41), chronic pulmonary diseases (aOR 1.24, 95% CI 1.08–1.42), malignancy (aOR 1.11, 95% CI 1.01–1.21), and rheumatic disease (aOR 1.27, 95% CI 1.01–1.59) were risk factors for potentially inadequate transfusions. CONCLUSIONS: More restrictive transfusion practices were adopted in general internal medicine and other clinics over time, suggesting that guideline recommendations and the Choosing Wisely initiative may have been increasingly followed. Interventions to reduce potentially inadequate transfusions should target providers who care for older patients and those with surgery or chronic cardiac and pulmonary diseases.
导言:临床实践指南和 2012 年发起的 "明智选择 "倡议建议,对病情稳定的住院患者输注红细胞的血红蛋白(Hb)阈值为 70-80 克/升。有关内科住院患者输血实践及其趋势的数据十分有限。为了填补这一空白,我们对普通内科和其他诊所的输血实践及其趋势进行了调查。方法:这项回顾性队列研究分析了瑞士一所大学医院 2012 年至 2019 年期间所有输注红细胞的住院患者的数据。如果可以获得输血前血红蛋白,我们将所有首次输血病例都纳入研究范围。主要终点是输血前平均血红蛋白;次要终点包括潜在输血不足(即血红蛋白≥80 g/l时的输血)和接受单个RBC单位。使用广义估计方程估计输血前平均血红蛋白随时间变化的趋势,并使用多变量调整广义估计方程模型确定潜在输血不足的风险因素。结果:在14598例输注红细胞的住院病人中,有1980人(13.6%)从普通内科出院。从2012年到2019年,普通内科的平均输血前血红蛋白从74.0克/升降至68.8克/升(平均年降幅为-0.76克/升,95%置信区间[CI] -0.51至-1.02),其他门诊的平均输血前血红蛋白从78.2克/升降至72.7克/升(平均年降幅为-0.69,95%置信区间[CI] -0.62至-0.77;交互作用P为0.53)。在研究期间,普通内科的潜在输血不足总比例为 17.8%,其他诊所为 24.1%(P <0.001),普通内科从 26.9% 降至 5.5%,其他诊所从 37.0% 降至 15.2%。相比之下,接受单个 RBC 单位的病例比例有所上升(普通内科从 39.5% 上升至 81.4%,其他诊所从 42.7% 上升至 66.1%)。年龄较大(≥65 岁与 <65 岁的调整赔率比 [aOR] 为 1.45,95% CI 为 1.32-1.58)、做过手术(aOR 为 1.24,95% CI 为 1.14-1.36)、急性大出血(aOR 为 1.16,95% CI 为 1.02-1.33)、慢性心力衰竭(aOR 为 1.17,95% CI 为 1.04-1.32)、缺血性心脏病(aOR 为 1.27,95% CI 1.15-1.41)、慢性肺部疾病(aOR 1.24,95% CI 1.08-1.42)、恶性肿瘤(aOR 1.11,95% CI 1.01-1.21)和风湿性疾病(aOR 1.27,95% CI 1.01-1.59)是潜在输血不足的危险因素。结论:随着时间的推移,普通内科和其他诊所采取了更严格的输血措施,这表明指南建议和 "明智选择 "倡议得到了越来越多的遵循。减少潜在输血不足的干预措施应针对老年患者、手术患者或慢性心肺疾病患者。
{"title":"Haemoglobin thresholds for transfusion: how are we doing in the era of Choosing Wisely? A retrospective cohort study","authors":"Phyranavy Jeganathan-Udayakumar, Nicole Tochtermann, Thomas Beck, M. Wertli, Christine Baumgartner","doi":"10.57187/smw.2023.40132","DOIUrl":"https://doi.org/10.57187/smw.2023.40132","url":null,"abstract":"INTRODUCTION: Clinical practice guidelines and the Choosing Wisely initiative launched in 2012 recommend a haemoglobin (Hb) threshold of 70–80 g/lfor red blood cell (RBC) transfusions in stable hospitalised patients. Data on transfusion practices and their trends in medical inpatients are limited. To address this gap, we investigated transfusion practices and their trends in general internal medicine and other clinics. METHODS: This retrospective cohort study analysed data from all hospitalisations with RBC transfusions at a Swiss university hospital between 2012 and 2019. We included all first transfusion episodes if pretransfusion Hb was available. The primary endpoint was mean pretransfusion Hb; secondary endpoints included potentially inadequate transfusions (i.e., transfusions at Hb ≥80 g/l) and receipt of a single RBC unit. Trends in mean pretransfusion Hb over time were estimated using generalised estimating equations, and risk factors for potentially inadequate transfusions were identified using multivariable adjusted generalised estimating equations models. RESULTS: Of 14,598 hospitalisations with RBC transfusions, 1980 (13.6%) were discharged from general internal medicine. From 2012 to 2019, mean pretransfusion Hb decreased from 74.0 g/l to 68.8 g/l in general internal medicine (mean annual decrease –0.76 g/l, 95% confidence interval [CI] –0.51 to –1.02) and from 78.2 g/l to 72.7 g/l in other clinics (mean annual decrease –0.69, 95% CI –0.62 to –0.77; p for interaction 0.53). The overall proportion of potentially inadequate transfusions was 17.8% in general internal medicine and 24.1% in other clinics (p <0.001) and decreased over the study period from 26.9% to 5.5% in general internal medicine and from 37.0% to 15.2% in other clinics. In contrast, the proportion of cases receiving a single RBC unit increased (39.5% to 81.4% in general internal medicine, 42.7% to 66.1% in other clinics). Older age (adjusted odds ratio [aOR] 1.45, 95% CI 1.32–1.58 for ≥65 vs <65 years), having surgery (aOR 1.24, 95% CI 1.14–1.36), acute haemorrhage (aOR 1.16, 95% CI 1.02–1.33), chronic heart failure (aOR 1.17, 95% CI 1.04–1.32), ischaemic heart diseases (aOR 1.27, 95% CI 1.15–1.41), chronic pulmonary diseases (aOR 1.24, 95% CI 1.08–1.42), malignancy (aOR 1.11, 95% CI 1.01–1.21), and rheumatic disease (aOR 1.27, 95% CI 1.01–1.59) were risk factors for potentially inadequate transfusions. CONCLUSIONS: More restrictive transfusion practices were adopted in general internal medicine and other clinics over time, suggesting that guideline recommendations and the Choosing Wisely initiative may have been increasingly followed. Interventions to reduce potentially inadequate transfusions should target providers who care for older patients and those with surgery or chronic cardiac and pulmonary diseases.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"48 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139212319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Launching SwissMedPreprints, the Swiss Medical Weekly's biomedical preprint server. 推出瑞士医学周刊的生物医学预印本服务器SwissMedPreprints。
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-28 DOI: 10.57187/s.3496
Adriano Aguzzi, Gérard Waeber
{"title":"Launching SwissMedPreprints, the Swiss Medical Weekly's biomedical preprint server.","authors":"Adriano Aguzzi, Gérard Waeber","doi":"10.57187/s.3496","DOIUrl":"10.57187/s.3496","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"153 ","pages":"s3496"},"PeriodicalIF":2.9,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138483071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
National survey in Switzerland calls for improved diagnosis and treatment in children with scabies 瑞士全国调查呼吁改善疥疮患儿的诊断和治疗
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-28 DOI: 10.57187/smw.2023.40129
Michael Buettcher
AIM OF THE STUDY: The global prevalence of scabies is estimated to be up to 200 million cases annually, with young children particularly affected. In Europe, most cases are thought to originate in migrant populations. Scabies management is challenging in children. To identify knowledge gaps and research needs, we aimed to descriptively evaluate the management of children with scabies by different Swiss healthcare providers. METHODS: An invitation for an anonymous online survey (36 questions) was sent to members of Swiss societies of dermatologists, general practitioners, paediatricians, paediatric dermatologists, paediatric infectious diseases specialists, and tropical medicine specialists, inviting clinicians to participate from 25th May to 8th August 2020. One reminder invitation was sent. Hospital pharmacies and the distributor of permethrin were contacted to report consumption trends of scabicides in 2018 and 2019. RESULTS: The survey was completed by 248 clinicians: 146 (59%) paediatricians, 47 (19%) dermatologists, 28 (11%) general practitioners, 6 (2%) paediatric dermatologists, 13 (5%) paediatric infectious diseases specialists, and 8 (3%) tropical medicine specialists. Most consulted up to 10 scabies cases within a 16-month period, with similar numbers in migrant and Swiss children. Dermoscopy was used by 24% of non-dermatologists. Non-dermatologists did not consider co-treatment of close contacts in up to 59% of cases. While permethrin was the first-line treatment, treatment failures were frequently reported in children aged <5 years. Up to 67% of paediatric dermatologists regularly used oral ivermectin off-label in children weighing <15 kg. None of the paediatric dermatologists, 15% of the dermatologists, and 9% of the non-dermatologists used only one treatment cycle.Scabicide consumption increased. Treatment studies on ivermectin use in children weighing <15 kg had the highest research priority. CONCLUSION: In Switzerland, scabies is a frequent dermatosis in migrant and Swiss children. While accessible, optimal diagnostics are underutilised, and treatment is suboptimal. Permethrin resistance appears to be an increasing problem. Dermatologists regularly use ivermectin off-label in children weighing <15 kg. Treatment studies on ivermectin use in children weighing <15 kg, user-friendly diagnostic tools, new treatment protocols, and child-friendly dosage forms are needed to improve the diagnosis and treatment of children with scabies.
研究目的:据估计,全球疥疮发病率每年高达 2 亿例,幼儿受影响尤为严重。在欧洲,大多数病例被认为源于移民人口。儿童疥疮的治疗具有挑战性。为了找出知识差距和研究需求,我们旨在对瑞士不同医疗机构对儿童疥疮患者的管理进行描述性评估。方法:我们向瑞士皮肤科医生、全科医生、儿科医生、儿科皮肤科医生、儿科传染病专家和热带医学专家协会的成员发出了匿名在线调查(36 个问题)的邀请,邀请临床医生在 2020 年 5 月 25 日至 8 月 8 日期间参与调查。还发出了一份提醒邀请函。与医院药房和氯菊酯经销商取得联系,以报告 2018 年和 2019 年杀疥剂的消费趋势。结果:248 名临床医生完成了调查:146人(59%)为儿科医生,47人(19%)为皮肤科医生,28人(11%)为全科医生,6人(2%)为儿科皮肤科医生,13人(5%)为儿科传染病专家,8人(3%)为热带医学专家。大多数医生在 16 个月内接诊了多达 10 个疥疮病例,移民儿童和瑞士儿童的疥疮病例数相似。24%的非皮肤科医生使用皮肤镜检查。在多达59%的病例中,非皮肤科医生没有考虑对密切接触者进行联合治疗。虽然氯菊酯是一线治疗方法,但小于5岁的儿童经常出现治疗失败的报告。多达 67% 的儿科皮肤科医生经常在标签外使用伊维菌素口服液治疗体重小于 15 千克的儿童。没有儿童皮肤科医生、15% 的皮肤科医生和 9% 的非皮肤科医生只使用一个治疗周期。对体重小于 15 千克的儿童使用伊维菌素的治疗研究具有最高的研究优先级。结论:在瑞士,疥疮是一种常见于移民儿童和瑞士儿童的皮肤病。虽然疥疮可以治愈,但最佳诊断方法却未得到充分利用,治疗效果也不理想。氯菊酯抗药性似乎是一个日益严重的问题。皮肤科医生经常在标签外使用伊维菌素治疗体重小于 15 千克的儿童。需要对体重小于 15 千克的儿童使用伊维菌素的情况进行治疗研究,并提供便于使用的诊断工具、新的治疗方案和便于儿童使用的剂型,以改善疥疮患儿的诊断和治疗。
{"title":"National survey in Switzerland calls for improved diagnosis and treatment in children with scabies","authors":"Michael Buettcher","doi":"10.57187/smw.2023.40129","DOIUrl":"https://doi.org/10.57187/smw.2023.40129","url":null,"abstract":"AIM OF THE STUDY: The global prevalence of scabies is estimated to be up to 200 million cases annually, with young children particularly affected. In Europe, most cases are thought to originate in migrant populations. Scabies management is challenging in children. To identify knowledge gaps and research needs, we aimed to descriptively evaluate the management of children with scabies by different Swiss healthcare providers. METHODS: An invitation for an anonymous online survey (36 questions) was sent to members of Swiss societies of dermatologists, general practitioners, paediatricians, paediatric dermatologists, paediatric infectious diseases specialists, and tropical medicine specialists, inviting clinicians to participate from 25th May to 8th August 2020. One reminder invitation was sent. Hospital pharmacies and the distributor of permethrin were contacted to report consumption trends of scabicides in 2018 and 2019. RESULTS: The survey was completed by 248 clinicians: 146 (59%) paediatricians, 47 (19%) dermatologists, 28 (11%) general practitioners, 6 (2%) paediatric dermatologists, 13 (5%) paediatric infectious diseases specialists, and 8 (3%) tropical medicine specialists. Most consulted up to 10 scabies cases within a 16-month period, with similar numbers in migrant and Swiss children. Dermoscopy was used by 24% of non-dermatologists. Non-dermatologists did not consider co-treatment of close contacts in up to 59% of cases. While permethrin was the first-line treatment, treatment failures were frequently reported in children aged <5 years. Up to 67% of paediatric dermatologists regularly used oral ivermectin off-label in children weighing <15 kg. None of the paediatric dermatologists, 15% of the dermatologists, and 9% of the non-dermatologists used only one treatment cycle.Scabicide consumption increased. Treatment studies on ivermectin use in children weighing <15 kg had the highest research priority. CONCLUSION: In Switzerland, scabies is a frequent dermatosis in migrant and Swiss children. While accessible, optimal diagnostics are underutilised, and treatment is suboptimal. Permethrin resistance appears to be an increasing problem. Dermatologists regularly use ivermectin off-label in children weighing <15 kg. Treatment studies on ivermectin use in children weighing <15 kg, user-friendly diagnostic tools, new treatment protocols, and child-friendly dosage forms are needed to improve the diagnosis and treatment of children with scabies.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"86 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139221194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Swiss digital Delphi study on patient-reported outcomes. 一项关于患者报告结果的瑞士数字德尔福研究。
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-21 DOI: 10.57187/smw.2023.40125
Matthew J Kerry, Thomas Volken, Nikola Biller-Andorno, Andrea Glässel, Markus Melloh

Aims of the study: Health-related quality of life (HRQoL) indicators are patient-reported outcomes (PROs). PROs are defined as any report of the status of a patient's health condition or health behaviour that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else. Despite Swiss national bodies (FOPH, FMH) recognising the potential of PRO measures (PROMs) for improving the health system, no consensus has yet emerged regarding a generic PROM framework or specific domains for practical uptake. The aim of the present digital Delphi study was to generate a consensual Swiss expert opinion on a generic PROM framework, measurement domains and items from a validated instrument (PROMIS [Patient-Reported Outcome Measurement Information System]) as well as on the role and implementation of PROs in the Swiss healthcare system via PRO consensus statements.

Methods: A 4-round digital Delphi study was conducted among Swiss PRO stakeholders. A total of n = 21 Swiss PROM stakeholders completed round 1 surveys on the PROM framework. During the stakeholder meeting, n = 11 stakeholders completed round 2 and round 3 surveys pertaining to measurement domains and items, respectively. In-meeting key questions and discussion items were extracted, consolidated into statements and subjected to consensus voting in a round 4, post-meeting survey. Consensus was defined as ≥70% agreement.

Results: Pre-meeting, agreement was reached for the tripartite framework of physical, mental and social health (95-100%). During the meeting, agreement was reached on all seven measurement domains of a generic PROM (PROMIS-29), ranging from 80% (Anxiety, Sleep Disturbance) to 100% (Pain Interference, Depression, Ability to Participate in Social Roles). Consensus was also reached for all PROMIS-29 items, with average domain consensus ranging from 83% (Sleep Disturbance, Ability to Participate in Social Roles) to 100% (Depression). Finally, four post-meeting consensus statements regarding PROs in Switzerland reached agreement.

Conclusions: A Delphi method can help identify areas of need regarding PROMs in Switzerland. The current study identified a generic PROM as a missing quality indicator for the Swiss national health system's value. A pre-meeting informational briefing, expert presentations and moderation supported three voting rounds to help identify PROMIS-29 as a PROM framework (round 1), measurement domains (round 2) and items (round 3) as a basis for further validation research. The empirical agreement among diverse stakeholders supports broad consensus towards preliminary feasibility of integrating generic PROMs into the Swiss health system based on content relevance.

研究目的:健康相关生活质量(HRQoL)指标是患者报告的结局(PROs)。病历的定义是直接由患者提供的关于患者健康状况或健康行为状况的任何报告,而无需临床医生或其他任何人对患者的反应进行解释。尽管瑞士国家机构(FOPH, FMH)认识到PRO措施(PROMs)改善卫生系统的潜力,但尚未就通用PROM框架或实际采用的特定领域达成共识。目前的数字德尔福研究的目的是就通用PROM框架、测量领域和经过验证的仪器(PROMIS[患者报告的结果测量信息系统])的项目,以及通过PRO共识声明,就PRO在瑞士医疗保健系统中的作用和实施,产生共识的瑞士专家意见。方法:对瑞士PRO利益相关者进行4轮数字德尔菲研究。共有n = 21名瑞士PROM利益相关者完成了关于PROM框架的第一轮调查。在涉众会议期间,n = 11个涉众分别完成了与度量领域和项目相关的第2轮和第3轮调查。会议上的关键问题和讨论项目被摘录并合并为发言,并在第4轮会议后调查中进行协商一致表决。共识定义为≥70%的同意。结果:会前,对身体、心理和社会健康三方框架达成一致(95% -100%)。会议期间,就通用PROM (promise -29)的所有七个测量领域达成了一致意见,范围从80%(焦虑、睡眠障碍)到100%(疼痛干扰、抑郁、参与社会角色的能力)。所有promise -29项目也达成了共识,平均共识范围从83%(睡眠障碍,参与社会角色的能力)到100%(抑郁)。最后,关于在瑞士的专业人员的四项会后协商一致声明达成了协议。结论:德尔菲法可以帮助确定瑞士prom的需求领域。目前的研究发现,通用PROM是瑞士国家卫生系统价值缺失的质量指标。会前的信息简报、专家介绍和审核支持了三轮投票,以帮助确定promise -29作为PROM框架(第一轮)、测量领域(第二轮)和项目(第三轮),作为进一步验证研究的基础。不同利益相关者之间的经验协议支持对基于内容相关性将通用prom整合到瑞士卫生系统的初步可行性达成广泛共识。
{"title":"A Swiss digital Delphi study on patient-reported outcomes.","authors":"Matthew J Kerry, Thomas Volken, Nikola Biller-Andorno, Andrea Glässel, Markus Melloh","doi":"10.57187/smw.2023.40125","DOIUrl":"10.57187/smw.2023.40125","url":null,"abstract":"<p><strong>Aims of the study: </strong>Health-related quality of life (HRQoL) indicators are patient-reported outcomes (PROs). PROs are defined as any report of the status of a patient's health condition or health behaviour that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else. Despite Swiss national bodies (FOPH, FMH) recognising the potential of PRO measures (PROMs) for improving the health system, no consensus has yet emerged regarding a generic PROM framework or specific domains for practical uptake. The aim of the present digital Delphi study was to generate a consensual Swiss expert opinion on a generic PROM framework, measurement domains and items from a validated instrument (PROMIS [Patient-Reported Outcome Measurement Information System]) as well as on the role and implementation of PROs in the Swiss healthcare system via PRO consensus statements.</p><p><strong>Methods: </strong>A 4-round digital Delphi study was conducted among Swiss PRO stakeholders. A total of n = 21 Swiss PROM stakeholders completed round 1 surveys on the PROM framework. During the stakeholder meeting, n = 11 stakeholders completed round 2 and round 3 surveys pertaining to measurement domains and items, respectively. In-meeting key questions and discussion items were extracted, consolidated into statements and subjected to consensus voting in a round 4, post-meeting survey. Consensus was defined as ≥70% agreement.</p><p><strong>Results: </strong>Pre-meeting, agreement was reached for the tripartite framework of physical, mental and social health (95-100%). During the meeting, agreement was reached on all seven measurement domains of a generic PROM (PROMIS-29), ranging from 80% (Anxiety, Sleep Disturbance) to 100% (Pain Interference, Depression, Ability to Participate in Social Roles). Consensus was also reached for all PROMIS-29 items, with average domain consensus ranging from 83% (Sleep Disturbance, Ability to Participate in Social Roles) to 100% (Depression). Finally, four post-meeting consensus statements regarding PROs in Switzerland reached agreement.</p><p><strong>Conclusions: </strong>A Delphi method can help identify areas of need regarding PROMs in Switzerland. The current study identified a generic PROM as a missing quality indicator for the Swiss national health system's value. A pre-meeting informational briefing, expert presentations and moderation supported three voting rounds to help identify PROMIS-29 as a PROM framework (round 1), measurement domains (round 2) and items (round 3) as a basis for further validation research. The empirical agreement among diverse stakeholders supports broad consensus towards preliminary feasibility of integrating generic PROMs into the Swiss health system based on content relevance.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"153 ","pages":"40125"},"PeriodicalIF":2.9,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138291870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital syphilis in Switzerland: a retrospective cohort study, 2010 to 2019. 瑞士先天性梅毒:2010年至2019年的回顾性队列研究
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-21 DOI: 10.57187/smw.2023.40121
Gioia Scherler, Maren Tomaske, Vincenzo Cannizzaro, Anna Steppacher, Franziska Zucol, Martin Theiler, Laurence Toutous Trellu, Anton Labutin, Philipp P Bosshard, Christoph Berger, Patrick M Meyer Sauteur
AIMS OF THE STUDY We previously reported a re-emergence of syphilis from 2006 to 2009 with detection of congenital syphilis in Switzerland. This study aimed to reassess the incidence of children exposed to maternal syphilis during pregnancy and congenital syphilis in a following 10-year period in the canton of Zurich, the most populous canton in Switzerland with the highest incidences of syphilis. METHODS Children were identified both by reviewing medical records at the four major neonatal and paediatric hospitals providing acute care in the canton of Zurich and by the serological database of the syphilis reference laboratory. Inclusion criteria for children were (a) date of birth in the period 2010-2019, (b) place of birth in the canton of Zurich, (c) evaluation for syphilis due to positive syphilis pregnancy screening and (d) age <1 year at diagnosis. Results were compared with epidemiological data provided by the Federal Office of Public Health (FOPH). RESULTS We identified and evaluated 17 children after potential exposure to maternal syphilis. Residual antibodies of a past infection were found in 11 mothers. Six children were identified as having had real exposure to asymptomatic maternal syphilis. From an epidemiological perspective, the distribution of the cases followed a similar pattern as confirmed syphilis cases in women of childbearing age reported to the FOPH. No cases of congenital syphilis were observed. CONCLUSIONS In contrast to the rise in syphilis infections, this study identified no cases of congenital syphilis in the canton of Zurich, Switzerland, in the period 2010-2019. Syphilis pregnancy screening may have prevented congenital syphilis by diagnosing and allowing adequate treatment of asymptomatic maternal syphilis.
研究目的:我们之前报道了2006年至2009年瑞士先天性梅毒检测中梅毒的再次出现。本研究旨在重新评估苏黎世州(瑞士人口最多、梅毒发病率最高的州)在怀孕期间暴露于母体梅毒和先天性梅毒的儿童发生率。方法:通过查看苏黎世州提供急性护理的四家主要新生儿和儿科医院的医疗记录以及梅毒参考实验室的血清学数据库来确定儿童。儿童的纳入标准为(a)出生日期为2010-2019年,(b)出生地点为苏黎世州,(c)因梅毒妊娠筛查阳性而对梅毒进行评估,(d)年龄。结果:我们确定并评估了17名可能暴露于母体梅毒的儿童。在11位母亲中发现了过去感染的残留抗体。6名儿童被确定为真正接触过无症状母体梅毒。从流行病学角度来看,这些病例的分布与向卫生局报告的育龄妇女确诊梅毒病例的分布模式相似。未发现先天性梅毒病例。结论:与梅毒感染的上升相反,本研究在2010-2019年期间在瑞士苏黎世州未发现先天性梅毒病例。梅毒妊娠筛查可能通过诊断和允许对无症状母体梅毒进行适当治疗来预防先天性梅毒。
{"title":"Congenital syphilis in Switzerland: a retrospective cohort study, 2010 to 2019.","authors":"Gioia Scherler, Maren Tomaske, Vincenzo Cannizzaro, Anna Steppacher, Franziska Zucol, Martin Theiler, Laurence Toutous Trellu, Anton Labutin, Philipp P Bosshard, Christoph Berger, Patrick M Meyer Sauteur","doi":"10.57187/smw.2023.40121","DOIUrl":"10.57187/smw.2023.40121","url":null,"abstract":"AIMS OF THE STUDY We previously reported a re-emergence of syphilis from 2006 to 2009 with detection of congenital syphilis in Switzerland. This study aimed to reassess the incidence of children exposed to maternal syphilis during pregnancy and congenital syphilis in a following 10-year period in the canton of Zurich, the most populous canton in Switzerland with the highest incidences of syphilis. METHODS Children were identified both by reviewing medical records at the four major neonatal and paediatric hospitals providing acute care in the canton of Zurich and by the serological database of the syphilis reference laboratory. Inclusion criteria for children were (a) date of birth in the period 2010-2019, (b) place of birth in the canton of Zurich, (c) evaluation for syphilis due to positive syphilis pregnancy screening and (d) age <1 year at diagnosis. Results were compared with epidemiological data provided by the Federal Office of Public Health (FOPH). RESULTS We identified and evaluated 17 children after potential exposure to maternal syphilis. Residual antibodies of a past infection were found in 11 mothers. Six children were identified as having had real exposure to asymptomatic maternal syphilis. From an epidemiological perspective, the distribution of the cases followed a similar pattern as confirmed syphilis cases in women of childbearing age reported to the FOPH. No cases of congenital syphilis were observed. CONCLUSIONS In contrast to the rise in syphilis infections, this study identified no cases of congenital syphilis in the canton of Zurich, Switzerland, in the period 2010-2019. Syphilis pregnancy screening may have prevented congenital syphilis by diagnosing and allowing adequate treatment of asymptomatic maternal syphilis.","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"153 ","pages":"40121"},"PeriodicalIF":2.9,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138291786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supplementum 274: Abstracts of the Swiss Oncology & Hematology Congress (SOHC). 附录274:瑞士肿瘤与血液学大会(SOHC)摘要
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-20 DOI: 10.57187/s.3469
Swiss Society Of Medical Oncology, Swiss Society Of Hematology, Swiss Group For Clinical Cancer Research
{"title":"Supplementum 274: Abstracts of the Swiss Oncology & Hematology Congress (SOHC).","authors":"Swiss Society Of Medical Oncology, Swiss Society Of Hematology, Swiss Group For Clinical Cancer Research","doi":"10.57187/s.3469","DOIUrl":"10.57187/s.3469","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"153 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138177332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Achilles tendon ultrasonography in the clinical screening of familial hypercholesterolaemia - a cross-sectional analysis. 跟腱超声在家族性高胆固醇血症临床筛查中的横断面分析。
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-20 DOI: 10.57187/smw.2023.40127
Maria De Montmollin, Sylvain Bétrisey, Martin Feller, Elisavet Moutzouri, Manuel R Blum, Jennifer Amsler, Dimitrios D Papazoglou, Burkhard Möller, Nicolas Rodondi

Background and aims: People with familial hypercholesterolaemia are 13 times more likely to develop cardiovascular disease than the general population. However, familial hypercholesterolaemia remains largely underdiagnosed. Tendon xanthoma is a specific clinical feature of familial hypercholesterolaemia and its presence alone implies a probable diagnosis of familial hypercholesterolaemia according to the Dutch Lipid Clinic Network Score (DLCNS). The aim of the study was to determine whether ultrasound detects more Achilles tendon xanthomas (ATX) than clinical examination.

Methods: We recruited 100 consecutive patients with LDL-C ≥4 mmol/l. Achilles tendons were evaluated through clinical examination by trained physicians and sonographic examination by another physician blind to the results of clinical examination. Blind second readings of ultrasound images were performed by an expert in musculoskeletal ultrasound. We compared the proportion of patients with ATX detected by either clinical examination or ultrasound and the proportion of patients with a probable/definite familial hypercholesterolaemia diagnosis on the DLCNS before and after ultrasound.

Results: Mean (SD) age was 47 (12) years; mean highest LDL-C was 6.57 mmol/l (2.2). ATX were detected in 23% of patients by clinical examination and in 60% by ultrasound. In consequence, 43% had a probable/definite diagnosis of familial hypercholesterolaemia on the DLCNS using clinical examination compared with 72% when ultrasound was used.

Conclusion: Compared to clinical examination, ultrasound examination of the Achilles tendon substantially improves the detection of ATX and may help to better identify patients with familial hypercholesterolaemia who are at high risk for premature cardiovascular disease.

背景和目的:家族性高胆固醇血症患者发生心血管疾病的可能性是一般人群的13倍。然而,家族性高胆固醇血症在很大程度上仍未得到诊断。肌腱黄瘤是家族性高胆固醇血症的一个特殊临床特征,根据荷兰脂质临床网络评分(DLCNS),其存在可能意味着家族性高胆固醇血症的诊断。该研究的目的是确定超声是否比临床检查更能检测出跟腱黄瘤(ATX)。方法:我们连续招募100例LDL-C≥4 mmol/l的患者。跟腱由训练有素的医生进行临床检查,另一名医生进行超声检查,对临床检查结果不知情。由肌肉骨骼超声专家对超声图像进行盲读。我们比较了通过临床检查或超声检查发现ATX的患者比例,以及超声前后DLCNS诊断为可能/明确家族性高胆固醇血症的患者比例。结果:平均(SD)年龄47(12)岁;平均最高LDL-C为6.57 mmol/l(2.2)。23%的患者通过临床检查发现ATX, 60%的患者通过超声检查发现ATX。因此,43%的患者通过临床检查可能/明确诊断为家族性高胆固醇血症,而超声检查为72%。结论:与临床检查相比,跟腱超声检查显著提高了ATX的检出率,有助于更好地识别家族性高胆固醇血症患者,这些患者是早发心血管疾病的高危人群。
{"title":"Achilles tendon ultrasonography in the clinical screening of familial hypercholesterolaemia - a cross-sectional analysis.","authors":"Maria De Montmollin, Sylvain Bétrisey, Martin Feller, Elisavet Moutzouri, Manuel R Blum, Jennifer Amsler, Dimitrios D Papazoglou, Burkhard Möller, Nicolas Rodondi","doi":"10.57187/smw.2023.40127","DOIUrl":"10.57187/smw.2023.40127","url":null,"abstract":"<p><strong>Background and aims: </strong>People with familial hypercholesterolaemia are 13 times more likely to develop cardiovascular disease than the general population. However, familial hypercholesterolaemia remains largely underdiagnosed. Tendon xanthoma is a specific clinical feature of familial hypercholesterolaemia and its presence alone implies a probable diagnosis of familial hypercholesterolaemia according to the Dutch Lipid Clinic Network Score (DLCNS). The aim of the study was to determine whether ultrasound detects more Achilles tendon xanthomas (ATX) than clinical examination.</p><p><strong>Methods: </strong>We recruited 100 consecutive patients with LDL-C ≥4 mmol/l. Achilles tendons were evaluated through clinical examination by trained physicians and sonographic examination by another physician blind to the results of clinical examination. Blind second readings of ultrasound images were performed by an expert in musculoskeletal ultrasound. We compared the proportion of patients with ATX detected by either clinical examination or ultrasound and the proportion of patients with a probable/definite familial hypercholesterolaemia diagnosis on the DLCNS before and after ultrasound.</p><p><strong>Results: </strong>Mean (SD) age was 47 (12) years; mean highest LDL-C was 6.57 mmol/l (2.2). ATX were detected in 23% of patients by clinical examination and in 60% by ultrasound. In consequence, 43% had a probable/definite diagnosis of familial hypercholesterolaemia on the DLCNS using clinical examination compared with 72% when ultrasound was used.</p><p><strong>Conclusion: </strong>Compared to clinical examination, ultrasound examination of the Achilles tendon substantially improves the detection of ATX and may help to better identify patients with familial hypercholesterolaemia who are at high risk for premature cardiovascular disease.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"153 ","pages":"40127"},"PeriodicalIF":2.9,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138177331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hair-thread strangulation syndrome in childhood: a systematic review. 儿童期丝线勒死综合征:一项系统综述。
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-09 DOI: 10.57187/smw.2023.40124
Daniela Djokic, Gregorio P Milani, Sebastiano A G Lava, Gianluca Gualco, Teresa Corigliano, Mario G Bianchetti, Camilla Lavagno

Introduction: Hair-thread strangulation syndrome describes the constriction of a body part by a tightly wound hair or thread. This research aims to review the literature about this entity.

Methods: A systematic review was performed to characterise hair-thread strangulation syndrome in subjects aged ≤16 years. This pre-registered review (PROSPERO ID: CRD42022363996) followed the PRISMA methodology.

Results: Subjects with digital strangulation were significantly younger (median = 4.0 [interquartile range: 2.0-6.1] months; n = 143) than females with genital strangulation (9.0 [6.8-11] years; n = 36), males with genital strangulation (5.1 [1.9-8.0] years; n = 36), and subjects with non-digital and non-genital strangulation (24 [13-48] months; n = 11). Digital strangulation was followed by an amputation in five (3.5%) and a reconstructive surgical intervention in seven (4.9%) cases. Sequelae occurred in four (11%) cases after female genital strangulation: clitoris autoamputation (n = 2) and surgical removal of a necrotic labium minus (n = 2). Severe complications were observed in 14 (39%) cases with male genital strangulation: urethral fistula (n = 7), urethral transection (n = 2), and partial penile autoamputation (n = 5). A partial uvular autoamputation was observed in one case (9.0%) with non-digital and non-genital strangulation.

Conclusions: Early recognition and management are crucial to avoid sequelae or long-term care in hair-thread strangulation syndrome.

简介:发丝勒死综合征描述的是身体部位被紧紧缠绕的头发或线头所束缚。本研究旨在回顾有关该实体的文献。方法:对年龄≤16岁的患者进行系统性评价。本次预注册评审(PROSPERO ID: CRD42022363996)采用PRISMA方法。结果:数字掐死的受试者明显更年轻(中位数= 4.0[四分位数间距:2.0-6.1]个月;N = 143)比女性生殖器勒死(9.0[6.8-11]岁;N = 36),男性生殖器勒死(5.1[1.9-8.0]岁;N = 36),非数字和非生殖器勒死的受试者(24[13-48]个月;N = 11)。5例(3.5%)数字绞杀后截肢,7例(4.9%)重建手术干预。女性生殖器绞窄术后出现后遗症4例(11%),分别为阴蒂自体截肢(n = 2)和坏死性阴唇切除(n = 2)。男性生殖器绞窄术后出现严重并发症14例(39%),分别为尿道瘘(n = 7)、尿道横断(n = 2)和部分阴茎自体截肢(n = 5)。非指、非生殖器绞窄术后出现部分小舌自体截肢1例(9.0%)。结论:早期认识和处理是避免丝线绞杀综合征后遗症和长期护理的关键。
{"title":"Hair-thread strangulation syndrome in childhood: a systematic review.","authors":"Daniela Djokic, Gregorio P Milani, Sebastiano A G Lava, Gianluca Gualco, Teresa Corigliano, Mario G Bianchetti, Camilla Lavagno","doi":"10.57187/smw.2023.40124","DOIUrl":"10.57187/smw.2023.40124","url":null,"abstract":"<p><strong>Introduction: </strong>Hair-thread strangulation syndrome describes the constriction of a body part by a tightly wound hair or thread. This research aims to review the literature about this entity.</p><p><strong>Methods: </strong>A systematic review was performed to characterise hair-thread strangulation syndrome in subjects aged ≤16 years. This pre-registered review (PROSPERO ID: CRD42022363996) followed the PRISMA methodology.</p><p><strong>Results: </strong>Subjects with digital strangulation were significantly younger (median = 4.0 [interquartile range: 2.0-6.1] months; n = 143) than females with genital strangulation (9.0 [6.8-11] years; n = 36), males with genital strangulation (5.1 [1.9-8.0] years; n = 36), and subjects with non-digital and non-genital strangulation (24 [13-48] months; n = 11). Digital strangulation was followed by an amputation in five (3.5%) and a reconstructive surgical intervention in seven (4.9%) cases. Sequelae occurred in four (11%) cases after female genital strangulation: clitoris autoamputation (n = 2) and surgical removal of a necrotic labium minus (n = 2). Severe complications were observed in 14 (39%) cases with male genital strangulation: urethral fistula (n = 7), urethral transection (n = 2), and partial penile autoamputation (n = 5). A partial uvular autoamputation was observed in one case (9.0%) with non-digital and non-genital strangulation.</p><p><strong>Conclusions: </strong>Early recognition and management are crucial to avoid sequelae or long-term care in hair-thread strangulation syndrome.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"153 ","pages":"40124"},"PeriodicalIF":2.9,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89719606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics governing treatment adjustment in COPD patients: results from the Swiss COPD cohort study. 控制COPD患者治疗调整的临床特征:来自瑞士COPD队列研究的结果
IF 2.9 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2023-11-04 DOI: 10.57187/smw.2023.40114
Lea Kleinsorge, Zahra Pasha, Maria Boesing, Nebal Abu Hussein, Pierre O Bridevaux, Prashant N Chhajed, Thomas Geiser, Ladina Joos Zellweger, Malcolm Kohler, Sabrina Maier, David Miedinger, Michael Tamm, Robert Thurnheer, Christophe Von Garnier, Joerg D Leuppi
<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a widespread chronic disease characterised by irreversible airway obstruction [1]. Features of clinical practice and healthcare systems for COPD patients can vary widely, even within similar healthcare structures. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy is considered the most reliable guidance for the management of COPD and aims to provide treating physicians with appropriate insight into the disease. COPD treatment adaptation typically mirrors the suggestions within the GOLD guidelines, depending on how the patient has been categorised. However, the present study posits that the reasons for adjusting COPD-related treatment are hugely varied.</p><p><strong>Objectives: </strong>The objective of this study was to assess the clinical symptoms that govern both pharmacological and non-pharmacological treatment changes in COPD patients. Using this insight, the study offers suggestions for optimising COPD management through the implementation of GOLD guidelines.</p><p><strong>Methods: </strong>In this observational cohort study, 24 general practitioners screened 260 COPD patients for eligibility from 2015-2019. General practitioners were asked to collect general information from patients using a standardised questionnaire to document symptoms. During a follow-up visit, the patient's symptoms and changes in therapy were assessed and entered into a central electronic database. Sixty-five patients were removed from the analysis due to exclusion criteria, and 195 patients with at least one additional visit within one year of the baseline visit were included in the analysis. A change in therapy was defined as a change in either medication or non-medical treatment, such as pulmonary rehabilitation. Multivariable mixed models were used to identify associations between given symptoms and a step up in therapy, a step down, or a step up and a step down at the same time.</p><p><strong>Results: </strong>For the 195 patients included in analyses, a treatment adjustment was made during 28% of visits. In 49% of these adjustments, the change in therapy was a step up, in 33% a step down and in 18% a step up (an increase) of certain treatment factors and a step down (a reduction) of other prescribed treatments at the same time. In the multivariable analysis, we found that the severity of disease was linked to the probability of therapy adjustment: patients in GOLD Group C were more likely to experience an increase in therapy compared to patients in GOLD Group A (odds ratio [OR] 3.43 [95% confidence interval {CI}: 1.02-11.55; p = 0.135]). In addition, compared to patients with mild obstruction, patients with severe (OR 4.24 [95% CI: 1.88-9.56]) to very severe (OR 5.48 [95% CI: 1.31-22.96]) obstruction were more likely to experience a therapy increase (p <0.0001). Patients with comorbidities were less likely to experience a treatment increase than those withou
背景:慢性阻塞性肺疾病(COPD)是一种以不可逆气道阻塞为特征的广泛存在的慢性疾病。慢性阻塞性肺病患者的临床实践和卫生保健系统的特点可能差别很大,即使在类似的卫生保健结构中也是如此。慢性阻塞性肺疾病全球倡议(GOLD)战略被认为是COPD管理最可靠的指南,旨在为治疗医生提供对该疾病的适当了解。COPD治疗适应通常反映GOLD指南中的建议,这取决于患者如何被分类。然而,本研究认为调整copd相关治疗的原因是多种多样的。目的:本研究的目的是评估影响COPD患者药物和非药物治疗变化的临床症状。利用这一见解,该研究通过实施GOLD指南为优化COPD管理提供了建议。方法:在这项观察性队列研究中,24名全科医生在2015-2019年筛选了260名COPD患者。全科医生被要求使用标准化问卷收集患者的一般信息以记录症状。在随访期间,评估患者的症状和治疗变化并将其输入中央电子数据库。65名患者因排除标准被从分析中剔除,195名在基线就诊后一年内至少有一次额外就诊的患者被纳入分析。治疗的改变被定义为药物治疗或非药物治疗的改变,如肺部康复。使用多变量混合模型来确定给定症状与治疗升级、降级或同时升级和降级之间的关联。结果:在分析的195例患者中,在28%的就诊期间进行了治疗调整。在这些调整中,49%的治疗变化是一个台阶,33%的是一个台阶,18%的是某些治疗因素的加强(增加)和其他规定治疗的减少(减少)。在多变量分析中,我们发现疾病的严重程度与治疗调整的概率有关:GOLD C组患者比GOLD A组患者更有可能增加治疗(优势比[OR] 3.43[95%可信区间{CI}: 1.02-11.55;P = 0.135])。此外,与轻度梗阻患者相比,严重(OR 4.24 [95% CI: 1.88-9.56])至非常严重(OR 5.48 [95% CI: 1.31-22.96])梗阻患者更有可能经历治疗增加(p 999;P = 0.109])。结论:这项队列研究为COPD患者在初级保健机构的管理提供了见解。COPD C组和气流限制GOLD 3-4均与COPD治疗增加相关。对于有合并症的患者,通常不改变治疗方法。病情恶化并没有增加治疗的可能性。既没有咳嗽/痰也没有高CAT评分与治疗的升级有关。
{"title":"Clinical characteristics governing treatment adjustment in COPD patients: results from the Swiss COPD cohort study.","authors":"Lea Kleinsorge, Zahra Pasha, Maria Boesing, Nebal Abu Hussein, Pierre O Bridevaux, Prashant N Chhajed, Thomas Geiser, Ladina Joos Zellweger, Malcolm Kohler, Sabrina Maier, David Miedinger, Michael Tamm, Robert Thurnheer, Christophe Von Garnier, Joerg D Leuppi","doi":"10.57187/smw.2023.40114","DOIUrl":"10.57187/smw.2023.40114","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Chronic obstructive pulmonary disease (COPD) is a widespread chronic disease characterised by irreversible airway obstruction [1]. Features of clinical practice and healthcare systems for COPD patients can vary widely, even within similar healthcare structures. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy is considered the most reliable guidance for the management of COPD and aims to provide treating physicians with appropriate insight into the disease. COPD treatment adaptation typically mirrors the suggestions within the GOLD guidelines, depending on how the patient has been categorised. However, the present study posits that the reasons for adjusting COPD-related treatment are hugely varied.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;The objective of this study was to assess the clinical symptoms that govern both pharmacological and non-pharmacological treatment changes in COPD patients. Using this insight, the study offers suggestions for optimising COPD management through the implementation of GOLD guidelines.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this observational cohort study, 24 general practitioners screened 260 COPD patients for eligibility from 2015-2019. General practitioners were asked to collect general information from patients using a standardised questionnaire to document symptoms. During a follow-up visit, the patient's symptoms and changes in therapy were assessed and entered into a central electronic database. Sixty-five patients were removed from the analysis due to exclusion criteria, and 195 patients with at least one additional visit within one year of the baseline visit were included in the analysis. A change in therapy was defined as a change in either medication or non-medical treatment, such as pulmonary rehabilitation. Multivariable mixed models were used to identify associations between given symptoms and a step up in therapy, a step down, or a step up and a step down at the same time.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;For the 195 patients included in analyses, a treatment adjustment was made during 28% of visits. In 49% of these adjustments, the change in therapy was a step up, in 33% a step down and in 18% a step up (an increase) of certain treatment factors and a step down (a reduction) of other prescribed treatments at the same time. In the multivariable analysis, we found that the severity of disease was linked to the probability of therapy adjustment: patients in GOLD Group C were more likely to experience an increase in therapy compared to patients in GOLD Group A (odds ratio [OR] 3.43 [95% confidence interval {CI}: 1.02-11.55; p = 0.135]). In addition, compared to patients with mild obstruction, patients with severe (OR 4.24 [95% CI: 1.88-9.56]) to very severe (OR 5.48 [95% CI: 1.31-22.96]) obstruction were more likely to experience a therapy increase (p &lt;0.0001). Patients with comorbidities were less likely to experience a treatment increase than those withou","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"153 11","pages":"40114"},"PeriodicalIF":2.9,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92156793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Swiss medical weekly
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1